Table 4.
Summary of results of included articles in the total group, as well as different disease groups n (%)
| Total number of patients | CD | UC | IBDu | Daily dose (mg)1 | Treatment years2 | Benefit3 | No benefit | Discontinuation | |
| 353 | 225 (64) | 119 (34) | 9 (2) | 20 | 268 | 228 (65) | 53 (15) | 72 (20) | |
| [10-80] | |||||||||
| Discontinuation | Response unknown4 | ||||||||
| Crohn’s disease (n = 225) | 141 | 118 (52) | 25 (11) | 40 (18) | 42 (19) | ||||
| Ulcerative colitis (n = 119) | 122 | 73 (62) | 16 (13) | 11 (9) | 19 (16) | ||||
1
Median start dose of thioguanine was 20 mg/d. This was adjusted based on symptoms and metabolite levels to doses of 10-80/d;
2
Treatment years are calculated based on sample size and median follow-up;
3
Defined as a clinically relevant decrease in disease activity scores by global physician assessment or when corticosteroids could be tapered or discontinued;
4
When results are not subdivided in disease entities (i.e., total results are given, but not for CD/UC). CD: Crohn’s disease; UC: Ulcerative colitis; IBDu: Inflammatory bowel disease unclassified.